Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RARA | P10276 | 5/20 | 0.45 |
| ▸ | RARB | P10826 | 5/20 | 0.45 |
| ▸ | RARG | P13631 | 5/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101913 | 0.89 | RARB (0.53) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL27557340 | 0.87 | RARB (0.45) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL8907172 | 0.84 | ATM (0.43) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL8109801 | 0.83 | CYP26A1 (0.46) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL21750652 | 0.82 | CYP1A2 (0.57) | KDM4ECYP26A1CYP26B1NPC1MAPT | |
| SCHEMBL30353262 | 0.81 | KDM4E (0.54) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL2240683 | 0.81 | RARB (0.64) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL7141574 | 0.81 | RARB (0.74) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL30134236 | 0.79 | KDM4E (0.53) | KDM4ERARARARBRARGRXRA | |
| SCHEMBL4945442 | 0.79 | RARA (0.38) | KDM4ERARARARBRARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7414143-B2 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-08-19 | — | — | US | disclosed |
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-05-18 | — | — | US | disclosed |
| WO-2005123713-A1 | PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6963002-B2 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050240029-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-10-27 | — | — | US | disclosed |
| EP-1280757-B1 | NEW GAMMA SELECTIVE RETINOIDS | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005003125-A1 | PROCESS FOR THE PREPARATION OF 4,4-DIMETHYL-6-ETHYNYLTHIOCHROMAN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1280757-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020026060-A1 | RAR selective retinoid agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | US | disclosed |
| WO-2001083438-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| EP-0907646-A1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997046548-A1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5654331-A | SKIN AND RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-08-05 | — | — | US | disclosed |
| US-5476860-A | Diaromatic compounds derived from a salicylic unit and their use in human and veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD GALDERMA) (FR) | 1995-12-19 | — | — | US | disclosed |
| US-4977276-A | ANTITUMOR AGENTS, SKIN DISORDERS | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIV. (US) | 1990-12-11 | — | — | US | disclosed |
| US-4833254-A | CHROMANYL, THIOCHROMANYL DERIVATIVES | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) | 1989-05-23 | — | — | US | disclosed |
| US-4826984-A | Heteroarotinoid compounds as anticancer agents | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGE ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | NAMPT, NAPRT, NNT | KDM4E 116/4885RARA 1989/4885RARB 2078/4885 |
| US-20020026060-A1 | RAR selective retinoid agonists | RARA, RARG, RARB | KDM4E 4717/4885RARA 1/4885RARB 3/4885 |
| US-20050240029-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | YAP1, SDHA, SDHB | KDM4E 30/4885RARA 1195/4885RARB 1175/4885 |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | CBR3, NR1H2, NR3C2 | KDM4E 2965/4885RARA 2569/4885RARB 2140/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | KDM4E 3446/4885RARA 4/4885RARB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.